TGF-β2 Protects the Small Intestine During Chemotherapy in Rats
Author Information
Author(s): van't Land B, Meijer H P, Frerichs J, Koetsier M, Jager D, Smeets R L, M'Rabet L, Hoijer M
Primary Institution: Numico-Research, Department of Condition and Disease Specific Research, Wageningen, The Netherlands
Hypothesis
Can Transforming Growth Factor-β2 reduce the side effects of methotrexate treatment in rats?
Conclusion
Oral supplementation with a TGF-β2 enriched fraction from bovine milk significantly reduced chemotherapy-associated weight loss and intestinal damage in rats.
Supporting Evidence
- Supplementation with TGF-β2 reduced weight loss in rats treated with methotrexate.
- TGF-β2 enriched fraction significantly restored villus length in the small intestine.
- Rats receiving TGF-β2 showed less intestinal damage compared to those receiving placebo.
Takeaway
This study found that a special protein from milk can help protect the intestines of rats from getting hurt by cancer medicine.
Methodology
Rats were given a TGF-β2 enriched fraction before and during methotrexate treatment, and their intestinal health was monitored.
Limitations
The study was conducted only in rats, and results may not directly translate to humans.
Participant Demographics
Eight-week old female Wag/Rij rats
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website